IDEXX Laboratories Inc (IDXX)vsMorgan Stanley (MS)
IDXX
IDEXX Laboratories Inc
$560.11
-2.11%
HEALTHCARE · Cap: $45.14B
MS
Morgan Stanley
$193.09
+1.54%
FINANCIAL SERVICES · Cap: $299.95B
Smart Verdict
WallStSmart Research — data-driven comparison
Morgan Stanley generates 1546% more annual revenue ($73.17B vs $4.45B). MS leads profitability with a 24.7% profit margin vs 24.6%. MS appears more attractively valued with a PEG of 2.33. MS earns a higher WallStSmart Score of 73/100 (B).
IDXX
Buy63
out of 100
Grade: C+
MS
Strong Buy73
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-41.2%
Fair Value
$459.52
Current Price
$560.11
$100.59 premium
Intrinsic value data unavailable for MS.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 73 in profit
Strong operational efficiency at 31.8%
Keeps 25 of every $100 in revenue as profit
Mega-cap, among the largest globally
Strong operational efficiency at 40.6%
Keeps 25 of every $100 in revenue as profit
Attractively priced relative to earnings
Reasonable price relative to book value
16.3% revenue growth
Areas to Watch
Expensive relative to growth rate
Premium valuation, high expectations priced in
Trading at 27.8x book value
Expensive relative to growth rate
Weak financial health signals
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : IDXX
The strongest argument for IDXX centers on Return on Equity, Operating Margin, Profit Margin. Profitability is solid with margins at 24.6% and operating margin at 31.8%. Revenue growth of 14.3% demonstrates continued momentum.
Bull Case : MS
The strongest argument for MS centers on Market Cap, Operating Margin, Profit Margin. Profitability is solid with margins at 24.7% and operating margin at 40.6%. Revenue growth of 16.3% demonstrates continued momentum.
Bear Case : IDXX
The primary concerns for IDXX are PEG Ratio, P/E Ratio, Price/Book. A P/E of 42.0x leaves little room for execution misses.
Bear Case : MS
The primary concerns for MS are PEG Ratio, Piotroski F-Score, Free Cash Flow.
Key Dynamics to Monitor
IDXX profiles as a mature stock while MS is a growth play — different risk/reward profiles.
IDXX carries more volatility with a beta of 1.57 — expect wider price swings.
MS is growing revenue faster at 16.3% — sustainability is the question.
IDXX generates stronger free cash flow (232M), providing more financial flexibility.
Bottom Line
MS scores higher overall (73/100 vs 63/100), backed by strong 24.7% margins and 16.3% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
IDEXX Laboratories Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets.
Morgan Stanley
FINANCIAL SERVICES · CAPITAL MARKETS · USA
Morgan Stanley is an American multinational investment bank and financial services company headquartered at 1585 Broadway in the Morgan Stanley Building, Midtown Manhattan, New York City.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?